Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Tris Pharma, Inc. clinical trials
The registry lists 22 studies whose lead sponsor is Tris Pharma, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 26, 2026.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Tris Pharma, Inc..
- Tris Pharma, Inc.22 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 22 of 22.
- A Study of Cebranopadol for the Treatment of Acute Pain After BunionectomyCompletedNCT06423703Phase 3
- A Study of Cebranopadol for the Treatment of Acute Pain After AbdominoplastyCompletedNCT06545097Phase 3
- A Study to Assess the Abuse Potential of Intranasal CebranopadolCompletedNCT06453265Phase 1
- Cebranopadol Effects on Ventilatory Drive, Central Nervous System (CNS) and Pain.CompletedNCT05491785Phase 1
- Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHDCompletedNCT03834766Phase 3
- Assessment of Abuse Potential of Cebranopadol in HumansCompletedNCT05256108Phase 1
- Amphetamine Extended Release Tablets and Driving Performance in Subjects With Attention Deficit/Hyperactivity Disorder (ADHD)CompletedNCT04027361Phase 2
- A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of CebranopadolCompletedNCT03882762Phase 1
- Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the NervesCompletedNCT01939366Phase 2
- Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy SubjectsCompletedNCT03958123Phase 1
- Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee PainCompletedNCT01709214Phase 2
- A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid UsersCompletedNCT03757559Phase 1
- Assessment of GRT6005 in Painful Osteoarthritis of the KneeCompletedNCT01357837Phase 2
- CORAL XT - Open-label Extension Trial of the CORAL TrialCompletedNCT02031432Phase 3
- Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain.CompletedNCT01725087Phase 2
- Bunionectomy Trial With GRT6005CompletedNCT00872885Phase 2
- Painful Diabetic Polyneuropathy Trial With a New Centrally Acting AnalgesicCompletedNCT00878293Phase 2
- Safety and Efficacy of GRT6005 in Pain Due to Diabetic PolyneuropathyCompletedNCT01347671Phase 2
- CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to CancerTerminatedNCT01964378Phase 3
- TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)CompletedNCT02083783Phase 3
- Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School StudyCompletedNCT03088267Phase 3
- Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 YearsCompletedNCT03610464Phase 4